Bristol Myers Squibb (BMY) Receivables (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Receivables for 18 consecutive years, with $10.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 18.73% year-over-year to $10.7 billion in Q2 2026; TTM through Jun 2026 was $10.7 billion, a 18.73% decrease from a year earlier, with the FY2025 full-year figure at $13.2 billion, up 6.03% from the prior year.
• Receivables was $10.7 billion for Q2 2026 at Bristol Myers Squibb, down from $10.8 billion in the prior quarter.
• Over five years, Receivables peaked at $13.2 billion in Q3 2025 and troughed at $9.9 billion in Q1 2022.
• A 5-year average of $11.7 billion and a median of $11.8 billion in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables rose 24.2% in 2023 and declined 18.73% in 2026, its largest moves.
• Over 5 years, Receivables stood at $10.4 billion in 2022, then gained by 9.11% to $11.3 billion in 2023, then fell by 1.81% to $11.1 billion in 2024, then increased by 4.26% to $11.6 billion in 2025, then declined by 8.14% to $10.7 billion in 2026.
• The last three Receivables figures came in at $10.7 billion (Q2 2026), $10.8 billion (Q1 2026), and $11.6 billion (Q4 2025), per Business Quant data.